| __timestamp | Amicus Therapeutics, Inc. | Ascendis Pharma A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 6274000 |
| Thursday, January 1, 2015 | 47269000 | 9415000 |
| Friday, January 1, 2016 | 71151000 | 11504000 |
| Sunday, January 1, 2017 | 88671000 | 13482000 |
| Monday, January 1, 2018 | 127200000 | 25057000 |
| Tuesday, January 1, 2019 | 169861000 | 48473000 |
| Wednesday, January 1, 2020 | 156407000 | 76669000 |
| Friday, January 1, 2021 | 192710000 | 160180000 |
| Saturday, January 1, 2022 | 213041000 | 221227000 |
| Sunday, January 1, 2023 | 275270000 | 264410000 |
| Monday, January 1, 2024 | 284545000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. Over the past decade, from 2014 to 2023, Ascendis Pharma A/S and Amicus Therapeutics, Inc. have shown significant trends in their Selling, General, and Administrative (SG&A) expenses.
Amicus Therapeutics, Inc.: Starting with SG&A expenses of approximately $20.7 million in 2014, Amicus saw a consistent rise, peaking at around $275 million in 2023. This represents a staggering increase of over 1,200%.
Ascendis Pharma A/S: Similarly, Ascendis began with $6.3 million in 2014, reaching $264 million by 2023, marking an impressive growth of over 4,000%.
These trends highlight the aggressive expansion and operational scaling of both companies, reflecting their strategic investments in growth and market presence.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.